Abstract
This chapter summarizes some important research works on prion AGAAAAGA, and presents three prion AGAAAAGA amyloid fibril models.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abskharon RN, Giachin G, Wohlkonig A, Soror SH, Pardon E, Legname G, Steyaert J (2014) Probing the N-terminal β-sheet conversion in the crystal structure of the human prion protein bound to a nanobody. J Am Chem Soc 136(3):937–944
Brown DR (2000) Prion protein peptides: optimal toxicity and peptide blockade of toxicity. Mol Cell Neurosci 15(1):66–78
Chabry J, Caughey B, Chesebro B (1998) Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem 273(21):13203–13207
Cheng HM, Tsai TWT, Huang WYC, Lee HK, Lian HY, Chou FC, Mou Y, Chu J, Chan JC (2011) Steric zipper formed by hydrophobic peptide fragment of Syrian hamster prion protein. Biochem 50(32):6815–6823
Garnier J, Osguthorpe DJ, Robson B (1978) Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. J Mol Biol 120(1):97–120
Gasset M, Baldwin MA, Lloyd DH, Gabriel JM, Holtzman DM, Cohen F, Fletterick R, Prusiner SB (1992) Predicted α-helical regions of the prion protein when synthesized as peptides form amyloid. Proc Natl Acad Sci U S A 89(22):10940–10944
Haigh CL, Edwards K, Brown DR (2005) Copper binding is the governing determinant of prion protein turnover. Mol Cell Neurosci 30(2):186–196
Holscher C, Delius H, Burkle A (1998) Overexpression of nonconvertible PrPC delta114–121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrPSc accumulation. J Virol 72(2):1153–1159
Jobling MF, Stewart LR, White AR, McLean C, Friedhuber A, Maher F, Beyreuther K, Masters CL, Barrow CJ, Collins SJ, Cappai R (1999) The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106–126. J Neurochem 73(4):1557–1565
Jones EM, Wu B, Surewicz K, Nadaud PS, Helmus JJ, Chen S, Jaroniec CP, Surewicz WK (2011) Structural polymorphism in amyloids: new insights from studies with Y145Stop prion protein fibrils. J Biol Chem 286(49):42777–42784
Kourie JI (2001) Mechanisms of prion-induced modifications in membrane transport properties: implications for signal transduction and neurotoxicity. Chem Biol Interact 138(1):1–26
Kourie JI, Kenna BL, Tew D, Jobling MF, Curtain CC, Masters CL, Barnham KJ, Cappai R (2003) Copper modulation of ion channels of PrP[106–126] mutant prion peptide fragments. J Membr Biol 193(1):35–45
Lee SW, Mou Y, Lin SY, Chou FC, Tseng WH, Chen C, Lu CYD, Yu SSF, Chan JCC (2008) Steric zipper of the amyloid fibrils formed by residues 109 to 122 of the Syrian hamster prion protein. J Mol Biol 378(5):1142–1154
Ma BY, Nussinov R (2002) Molecular dynamics simulations of alanine rich β-sheet oligomers: insight into amyloid formation. Protein Sci 11(10):2335–2350
Norstrom EM, Mastrianni JA (2005) The AGAAAAGA palindrome in PrP is required to generate a productive PrPSc-PrPC complex that leads to prion propagation. J Biol Chem 280(29):27236–27243
Sasaki K, Gaikwad J, Hashiguchi S, Kubota T, Sugimura K, Kremer W, Kalbitzer HR, Akasaka K (2008) Reversible monomer-oligomer transition in human prion protein. Prion 2(3):118–122
Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJ, McFarlane HT, Madsen A, Riekel C, Eisenberg D (2007) Atomic structures of amyloid cross-β spines reveal varied steric zippers. Nature 447(7143):453–457
Wagoner VA, Cheon M, Chang I, Hall CK (2011) Computer simulation study of amyloid fibril formation by palindromic sequences in prion peptides. Proteins Struct Funct Bioinf 79(7):2132–2145
Wegner C, Romer A, Schmalzbauer R, Lorenz H, Windl O, Kretzschmar HA (2002) Mutant prion protein acquires resistance to protease in mouse neuroblastoma cells. J Gen Virol 83(Pt 5):1237–1245
Zanuy D, Ma B, Nussinov R (2003) Short peptide amyloid organization: stabilities and conformations of the islet amyloid peptide NFGAIL. Biophys J 84(3):1884–1894
Zhang JP (2011) Optimal molecular structures of prion AGAAAAGA amyloid fibrils formatted by simulated annealing. J Mol Model 17(1):173–179
Zhang JP (2011) Comparison studies of the structural stability of rabbit prion protein with human and mouse prion proteins. J Theory Biol 269(1):88–95
Zhang JP (2011) Molecular dynamics – practical application – mechanism underlying the resistance to prion diseases in rabbits. LAP Lambert Academic Publishing: Saarbrücken. ISBN:978-3-8465-4843-1
Zhang JP (2011) Practical global optimization computing methods in molecular modelling – for atom-resolution structures of amyloid fibrils, 1st Version. LAP Lambert Academic Publishing: Saarbrücken. ISBN:978-3-8465-2139-7
Zhang JP (2012) Molecular dynamics studies on the structural stability of wild-type rabbit prion protein: surface electrostatic charge distributions. In: Battik C, Belhassine K (eds) Bioinformatics research: new developments. NOVA Science Publishers, New York, Chapter 7, pp 131–8. ISBN:978-1-61942-363-3
Zhang JP, Sun J, Wu CZ (2011) Optimal atomic-resolution structures of prion AGAAAAGA amyloid fibrils. J Theory Biol 279(1):17–28
Zhang X, Zhou X, Ding T, Gan W, Yang L, Yin X, Zhao D (2012) Polymorphisms of SPRN (shadow of prion protein homology) in three breeds of sheep in China. Virus Genes 44(3):548–550
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Zhang, J. (2015). A Summary of the Research Works on AGAAAAGA. In: Molecular Structures and Structural Dynamics of Prion Proteins and Prions. Focus on Structural Biology, vol 9. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7318-8_18
Download citation
DOI: https://doi.org/10.1007/978-94-017-7318-8_18
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-7317-1
Online ISBN: 978-94-017-7318-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)